These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 17954689)

  • 1. Betulinic acid derivatives that target gp120 and inhibit multiple genetic subtypes of human immunodeficiency virus type 1.
    Lai W; Huang L; Ho P; Li Z; Montefiori D; Chen CH
    Antimicrob Agents Chemother; 2008 Jan; 52(1):128-36. PubMed ID: 17954689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of human immunodeficiency virus (HIV) type 1 envelope in the anti-HIV activity of the betulinic acid derivative IC9564.
    Holz-Smith SL; Sun IC; Jin L; Matthews TJ; Lee KH; Chen CH
    Antimicrob Agents Chemother; 2001 Jan; 45(1):60-6. PubMed ID: 11120945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-AIDS agents 49. Synthesis, anti-HIV, and anti-fusion activities of IC9564 analogues based on betulinic acid.
    Sun IC; Chen CH; Kashiwada Y; Wu JH; Wang HK; Lee KH
    J Med Chem; 2002 Sep; 45(19):4271-5. PubMed ID: 12213068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and anti-HIV activity of bi-functional betulinic acid derivatives.
    Huang L; Ho P; Lee KH; Chen CH
    Bioorg Med Chem; 2006 Apr; 14(7):2279-89. PubMed ID: 16314103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conformation of gp120 determines the sensitivity of HIV-1 DH012 to the entry inhibitor IC9564.
    Yuan X; Huang L; Ho P; Labranche C; Chen CH
    Virology; 2004 Jul; 324(2):525-30. PubMed ID: 15207637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bifunctional anti-human immunodeficiency virus type 1 small molecules with two novel mechanisms of action.
    Huang L; Yuan X; Aiken C; Chen CH
    Antimicrob Agents Chemother; 2004 Feb; 48(2):663-5. PubMed ID: 14742233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of a nonproductive conformational change in gp120 by a small molecule HIV type 1 entry inhibitor.
    Huang L; Lai W; Ho P; Chen CH
    AIDS Res Hum Retroviruses; 2007 Jan; 23(1):28-32. PubMed ID: 17263629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation and Inactivation of Primary Human Immunodeficiency Virus Envelope Glycoprotein Trimers by CD4-Mimetic Compounds.
    Madani N; Princiotto AM; Zhao C; Jahanbakhshsefidi F; Mertens M; Herschhorn A; Melillo B; Smith AB; Sodroski J
    J Virol; 2017 Feb; 91(3):. PubMed ID: 27881646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Betulinic acid derivatives as human immunodeficiency virus type 2 (HIV-2) inhibitors.
    Dang Z; Lai W; Qian K; Ho P; Lee KH; Chen CH; Huang L
    J Med Chem; 2009 Dec; 52(23):7887-91. PubMed ID: 19526990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor.
    Kuhmann SE; Pugach P; Kunstman KJ; Taylor J; Stanfield RL; Snyder A; Strizki JM; Riley J; Baroudy BM; Wilson IA; Korber BT; Wolinsky SM; Moore JP
    J Virol; 2004 Mar; 78(6):2790-807. PubMed ID: 14990699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kinetic factors control efficiencies of cell entry, efficacies of entry inhibitors, and mechanisms of adaptation of human immunodeficiency virus.
    Platt EJ; Durnin JP; Kabat D
    J Virol; 2005 Apr; 79(7):4347-56. PubMed ID: 15767435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. V3 loop truncations in HIV-1 envelope impart resistance to coreceptor inhibitors and enhanced sensitivity to neutralizing antibodies.
    Laakso MM; Lee FH; Haggarty B; Agrawal C; Nolan KM; Biscone M; Romano J; Jordan AP; Leslie GJ; Meissner EG; Su L; Hoxie JA; Doms RW
    PLoS Pathog; 2007 Aug; 3(8):e117. PubMed ID: 17722977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics.
    Reeves JD; Gallo SA; Ahmad N; Miamidian JL; Harvey PE; Sharron M; Pohlmann S; Sfakianos JN; Derdeyn CA; Blumenthal R; Hunter E; Doms RW
    Proc Natl Acad Sci U S A; 2002 Dec; 99(25):16249-54. PubMed ID: 12444251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140.
    Trkola A; Ketas TJ; Nagashima KA; Zhao L; Cilliers T; Morris L; Moore JP; Maddon PJ; Olson WC
    J Virol; 2001 Jan; 75(2):579-88. PubMed ID: 11134270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutations That Increase the Stability of the Postfusion gp41 Conformation of the HIV-1 Envelope Glycoprotein Are Selected by both an X4 and R5 HIV-1 Virus To Escape Fusion Inhibitors Corresponding to Heptad Repeat 1 of gp41, but the gp120 Adaptive Mutations Differ between the Two Viruses.
    Zhuang M; Vassell R; Yuan C; Keller PW; Ling H; Wang W; Weiss CD
    J Virol; 2019 Jun; 93(11):. PubMed ID: 30894471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis of betulinic acid derivatives as entry inhibitors against HIV-1 and bevirimat-resistant HIV-1 variants.
    Dang Z; Qian K; Ho P; Zhu L; Lee KH; Huang L; Chen CH
    Bioorg Med Chem Lett; 2012 Aug; 22(16):5190-4. PubMed ID: 22818973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple antiviral activities of cyanovirin-N: blocking of human immunodeficiency virus type 1 gp120 interaction with CD4 and coreceptor and inhibition of diverse enveloped viruses.
    Dey B; Lerner DL; Lusso P; Boyd MR; Elder JH; Berger EA
    J Virol; 2000 May; 74(10):4562-9. PubMed ID: 10775592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural variation in the V3 crown of human immunodeficiency virus type 1 affects replicative fitness and entry inhibitor sensitivity.
    Lobritz MA; Marozsan AJ; Troyer RM; Arts EJ
    J Virol; 2007 Aug; 81(15):8258-69. PubMed ID: 17522224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis, and evaluation of HIV-1 entry inhibitors based on broadly neutralizing antibody 447-52D and gp120 V3loop interactions.
    Senapathi J; Bommakanti A; Vangara S; Kondapi AK
    Bioorg Chem; 2021 Nov; 116():105313. PubMed ID: 34517280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Understanding the structure-activity relationship of betulinic acid derivatives as anti-HIV-1 agents by using 3D-QSAR and docking.
    Lan P; Chen WN; Huang ZJ; Sun PH; Chen WM
    J Mol Model; 2011 Jul; 17(7):1643-59. PubMed ID: 20978914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.